Skip to main content
Midas Edge

BRAINSTORM CELL THERAPEUTICS INC.

For the period ended Mar 31, 2026. Filed May 15, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

BCLI$0.97+1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Interim Condensed Statements of Changes in Stockholders’ Equity (Deficit)

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)****(UNAUDITED)

​​​​​​​​​​​​​
​​​​​​Additional​​​​​Total
​ · ​ · Common stock · ​ · paid-in · ​ · Treasury · ​ · Accumulated · ​ · stockholders’
​​ ​ ​Number​ ​ ​Amount​ ​ ​capital​ ​ ​stocks​ ​ ​deficit​ ​ ​deficit
Balance as of January 1, 20256,141,762​14​218,974​(116)​(226,636)​(7,764)
Stock-based compensation related to stock and options granted to directors and employees—​*​717​—​—​717
Issuance of shares in at-the-market (ATM) offering, net (Note 4)​388,059​*​685​—​—​685
Exercise of warrants (Note 4)​1,381,383​1​1,768​—​—​1,769
Net loss—​—​—​—​(2,864)​(2,864)
Balance as of March 31, 2025​7,911,204​15​222,144​(116)​(229,500)​(7,457)
  • Represents an amount less than $1.

** During the reporting period, the Company settled outstanding accounts payable to a supplier in the amount of $450 through the issuance of 281,250 shares of common stock. This transaction was accounted for as a debt-for-equity swap.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)

​​​​​​​​​​​​​
​​​​​​Additional​​​​​Total
​ · ​ · Common stock · ​ · paid-in · ​ · Treasury · ​ · Accumulated · ​ · stockholders’
​​ ​ ​Number​ ​ ​Amount​ ​ ​capital​ ​ ​stocks​ ​ ​deficit​ ​ ​deficit
Balance as of January 1, 202611,034,775​16​227,058​(116)​(236,943)​(9,985)
Stock-based compensation related to stock and options granted to directors and employees—​—​133​—​—​133
Issuance of shares for private placement, net (Note 4)​—​—​970​—​—​970
Net loss​—​—​—​—​(2,127)​(2,127)
Balance as of March 31, 2026​11,034,775​16​228,161​(116)​(239,070)​(11,009)
  • Represents an amount less than $1.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.